The article has been automatically translated into English by Google Translate from Russian and has not been edited.
Переклад цього матеріалу українською мовою з російської було автоматично здійснено сервісом Google Translate, без подальшого редагування тексту.
Bu məqalə Google Translate servisi vasitəsi ilə avtomatik olaraq rus dilindən azərbaycan dilinə tərcümə olunmuşdur. Bundan sonra mətn redaktə edilməmişdir.

Russia and Ukraine treat COVID-19 with outdated methods: pharmaceutical companies urge to update recommendations

The Association of Clinical Research Organizations (AOKI), which includes world pharmaceutical companies, sent a request to the Russian Ministry of Health to exclude hydroxychloroquine, lopinavir and ritonavir from the guidelines for the treatment of coronavirus. A few days ago, another cessation of studies of these drugs for the treatment of patients with COVID-19 was announced at WHO. Writes about it with the BBC.

Photo: Shutterstock

The current recommendations "are poorly consistent with the latest data on adequate treatment," the letter says in AOKI.

In the training manual of the Ministry of Health, it is proposed to use hydroxychloroquine and mefloquine close to it, which usually treat rheumatoid arthritis and malaria, including for the prevention of coronavirus. A combination of lopinavir and ritonavir, the drugs used to treat HIV infection, is also recommended.

“All these drugs, according to the results of recent studies, can be considered as having lost the status of potentially effective for a new coronavirus infection,” the association said in a letter.

The Food and Drug Administration (FDA) revoked the emergency use of hydroxychloroquine and chloroquine for the treatment of coronavirus, the authors note, and the WHO stopped recruiting patients for the hydroxychloroquine study group.

In the current version of domestic guidelines, hydroxychloroquine and the combination of lopinavir-ritonavir appear in 12 of 16 treatment regimens for mild, moderate and severe forms of the disease caused by the new coronavirus, the letter said.

The authors say that they are “extremely alarmed” by the fact that hydroxychloroquine was widely used among Moscow doctors to prevent coronavirus infection. Among them, the prevention program with this drug was completed on June 17, the Moscow Department of Health said in response to a request from AOKI.

“According to the progress report of the said“ prevention program ”, more than four thousand medical workers were exposed to unnecessary risk for several months on the basis of the current recommendations of the Russian Ministry of Health,” the letter said. In support of their position, pharmaceutical companies provide a link to a study that says that the use of hydroxychloroquine for prevention does not give advantages compared with placebo, but the likelihood of adverse events is greater.

Instead of these drugs, AOKI is urged to include dexamethasone, which is used in the treatment of autoimmune, infectious and rheumatic diseases, and which is now called the first drug in WHO who showed a decrease in mortality in severe patients with Covid-19.

On the subject: 'Save lives around the world': a cheap and popular drug reduces mortality from COVID-19

AOKI is a non-profit organization uniting participants in the Russian clinical research market. In particular, it includes the world's largest pharmaceutical companies Pfizer, AstraZeneca, Bayer, etc.

The Ministry of Health, in response to a request from journalists regarding the letter, explained that the recommendations were revised “in an expeditious manner when new scientific data, results of clinical trials and registration of new drugs appear”. The working group conducts a comprehensive assessment of the effectiveness and safety of the use of various drugs in different categories of patients, the department noted.

What the WHO and FDA said about these drugs

On Saturday, July 4, WHO announced the suspension of trials of hydroxychloroquine and a combination of lopinavir and ritonavir. This recommendation was made by the international Steering Committee for Test Solidarity, which was created by the organization to seek effective treatment for patients hospitalized with coronavirus.

According to preliminary data, hydroxychloroquine and lopinavir / ritonavir do not significantly help to reduce mortality among patients with coronavirus or do not affect it at all, according to the WHO.

An FDA review released Wednesday, July 1, says patients who are treated with hydroxychloroquine and chloroquine may experience heart rhythm disturbances and other complications related to blood and lymphatic system diseases, kidney damage, and liver problems.

For the first time, WHO suspended a study of hydroxychloroquine a month ago. Then the reason was a study published in the journal Lancet, in which it was concluded that the use of hydroxyloroquine is ineffective, and can also increase the likelihood of patient death.

The magazine later issued a rebuttal of the publication, which stated that the underlying data was provided by a little-known company Surgisphere, and it was probably incorrect. WHO then stated that it was ready to continue research.

The fact that he takes hydroxychloroquine for preventive purposes, said US President Donald Trump. In June, he said that he had drunk a two-week course.

Hydroxychloroquine is a later and less toxic version of the drug chloroquine and has a more pronounced antiviral and anti-inflammatory effect.

On the subject: What is treated with COVID-19: list of drugs and conditions for their use

Chloroquine is usually prescribed for the treatment of malaria, certain protozoal infections, rheumatoid arthritis, and lupus erythematosus.

Both drugs have cardiotoxicity and can cause arrhythmias and tachycardia, especially in patients with existing cardiovascular diseases, the U.S. Food and Drug Administration warned.

Ukraine is negotiating the purchase of Remdesivira

As of the end of June, Ukraine still used antimalarial drugs to treat coronavirus.

On June 8, it became known that the Ministry of Health of Ukraine is negotiating the possibility of purchasing the drug Remdesivir in an amount sufficient to treat 19 thousand patients from COVID-8, writes "Ukrinform".

This was announced at a briefing by the Minister of Health Maxim Stepanov.

“We have already held certain negotiations with companies that have received a license from Gilead. We are counting on the purchase of this drug. Previously, there is an agreement to purchase it in an amount calculated for treatment in 8 thousand patients. Now we are negotiating. This is a drug that can be effectively used in the treatment of coronavirus disease, ”said Stepanov.

He noted that Remdesivir was included by Ukrainian specialists in the treatment protocol COVID-19.

As ForumDaily wrote earlier:

Miscellaneous treatment At home coronavirus

Read also on ForumDaily:

What may be the consequences of the asymptomatic course of COVID-19: personal experience

Doctors have discovered brain damage in children with a mysterious syndrome associated with COVID-19

Scientists have managed to create a vaccine against COVID-19, which has proven efficacy in two phases of trials

How much will remdesivir treatment cost for Americans with COVID-19

Let's face the crisis together and support each other

No one in the world expected a coronavirus pandemic, but she came in disrupting the usual rhythm of life and work of billions of people, causing panic and uncertainty about tomorrow.

ForumDaily also faced financial difficulties due to the loss of some advertisers due to the economic downturn and quarantine. But we are not reducing the number of materials and the mode of operation, since we want our readers to receive timely and up-to-date information in this difficult time. In addition, we support Local small businesses in the USA that suffer the most.

But ForumDaily is also a small business. Despite the loss of part of the income, we are doing our best to ensure that you are informed and armed with all the necessary knowledge to counter the pandemic and resolve other important issues during quarantine.

To maintain this rhythm of work, we need your help. We will be grateful for any amount that you are willing to allot to support our team.

Let's face the crisis together!

Security of contributions is guaranteed by the use of the highly secure Stripe system.

Always yours, ForumDaily!

Do you want more important and interesting news about life in the USA and immigration to America? Subscribe to our page in Facebook. Choose the option "Priority in the show" - and read us first. And don't forget to subscribe to ForumDaily Woman and ForumDaily New York - there you will find a lot of interesting and positive information.

1043 requests in 1,828 seconds.